Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa

GlobeNewswire October 6, 2017

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

GlobeNewswire October 4, 2017

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

GlobeNewswire September 28, 2017

12 Biggest Mid-Day Losers For Friday

Benzinga.com  September 22, 2017

Abeona Therapeutics Announces Upcoming Conference Participation

GlobeNewswire September 22, 2017

Technical Snapshots for These Biotech Stocks -- ImmunoCellular Therapeutics, Protalix BioTherapeutics, Synthetic Biologics, and Abeona Therapeutics

PR Newswire September 22, 2017

Mid-Afternoon Market Update: Dow Rises Over 50 Points; T2 Biosystems Shares Plummet

Benzinga.com  September 15, 2017

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 15, 2017

Mid-Day Market Update: Mirati Therapeutics Climbs Following Positive Sitravatinib Data; First Internet Bancorp Shares Slide

Benzinga.com  September 15, 2017

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 29, 2017

Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

GlobeNewswire August 29, 2017

From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017

Benzinga.com  August 25, 2017

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

GlobeNewswire August 17, 2017

Stock Performance Review on Biotech Industry -- Radius Health, Abeona Therapeutics, Catalyst Biosciences, and Cerecor

PR Newswire August 17, 2017

Watch These 3 Huge Call Purchases In Wednesday Trade

Benzinga.com  August 16, 2017

Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

GlobeNewswire August 15, 2017

Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer

GlobeNewswire July 25, 2017

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

GlobeNewswire July 18, 2017

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

GlobeNewswire June 29, 2017

6 Biotech Stocks Jefferies Says Are Undervalued

Benzinga.com  June 23, 2017